Greenhawt Matthew J. 4

What Happened

• Matthew J. Greenhawt, Chief Medical Officer of Aquestive Therapeutics (AQST), was granted equity awards on March 9, 2026: 75,000 restricted shares reported at $0 and a derivative option award for 50,000 shares with an exercise price of $4.29 (recorded value $214,500). These are grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely).
• Grants: 75,000 restricted common shares (reported at $0); 50,000-share option grant @ $4.29 = $214,500 (derivative).
• Vesting: Restricted shares vest in three annual installments (25% / 25% / 50%) per footnote F1; the option vests on the same 25% / 25% / 50% schedule per F2.
• Shares owned after transaction: not disclosed in the provided filing summary.
• No 10b5-1 plan, tax-withholding sale, or sale transaction reported in this filing.

Context

• These are standard compensation awards to an executive rather than purchases or sales. The option gives the holder the right to buy shares at $4.29 after vesting; the restricted shares will convert to freely tradable shares only as they vest. Such grants are common for retention and incentive pay and do not by themselves indicate short-term insider sentiment.